BioSpace News Archive

The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.

Funding to scale-up company’s proprietary technology C-Stem™ for mass-production of safe and affordable cell therapies

At the Annual General Meeting in Recipharm AB on May 13, 2019, the shareholders adopted the resolutions summarized

Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developments

Auris Medical Holding Ltd. announced the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares.

One of the largest, most ethnically diverse studies of Parkinson’s disease to uncover the genetic basis of one of the most common neurodegenerative disorders

Polarean Imaging plc announces an update regarding the Company’s Phase III Clinical Trials.

The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.

The company said that its lead product was creating greater-than anticipated kidney injuries in trial patients.

The new guidance should allow switches from branded products to biosimilars that are alike in safety and efficacy without prescriber approval.